Stryker Corporation (NYSE:SYK) Shares Sold by Trek Financial LLC

Trek Financial LLC lessened its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 93.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 612 shares of the medical technology company's stock after selling 9,355 shares during the period. Trek Financial LLC's holdings in Stryker were worth $228,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mascoma Wealth Management LLC increased its position in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after acquiring an additional 27 shares in the last quarter. Continuum Advisory LLC raised its position in shares of Stryker by 5.8% during the 1st quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company's stock valued at $198,000 after buying an additional 29 shares in the last quarter. Oakworth Capital Inc. raised its position in shares of Stryker by 0.5% during the 1st quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company's stock valued at $2,283,000 after buying an additional 29 shares in the last quarter. Ironwood Investment Counsel LLC raised its position in Stryker by 0.9% in the 4th quarter. Ironwood Investment Counsel LLC now owns 3,323 shares of the medical technology company's stock worth $1,196,000 after purchasing an additional 30 shares during the period. Finally, ICW Investment Advisors LLC grew its holdings in Stryker by 0.6% in the 4th quarter. ICW Investment Advisors LLC now owns 4,846 shares of the medical technology company's stock worth $1,745,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of Stryker stock traded down $5.04 during trading on Friday, hitting $389.73. The stock had a trading volume of 338,672 shares, compared to its average volume of 1,457,756. The firm has a market cap of $148.75 billion, a price-to-earnings ratio of 52.67, a P/E/G ratio of 2.96 and a beta of 0.91. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19. The business's 50-day moving average is $384.57 and its 200 day moving average is $376.97.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same period last year, the business earned $2.50 earnings per share. The business's revenue was up 11.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker's dividend payout ratio is currently 45.41%.

Insider Activity

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Roth Mkm lifted their target price on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Truist Financial upped their price target on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. BTIG Research set a $403.00 price target on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, Wall Street Zen downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $428.55.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.